University of California San Francisco

COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. (25894502)

Watkin LB, Jessen B, Wiszniewski W, Vece TJ, Jan M, Sha Y, Thamsen M, Santos-Cortez RL, Lee K, Gambin T, Forbes LR, Law CS, Stray-Pedersen A, Cheng MH, Mace EM, Anderson MS, Liu D, Tang LF, Nicholas SK, Nahmod K, Makedonas G, Canter DL, Kwok PY, Hicks J, Jones KD, Penney S, Jhangiani SN, Rosenblum MD, Dell SD, Waterfield MR, Papa FR, Muzny DM, Zaitlen N, Leal SM, Gonzaga-Jauregui C, Baylor-Hopkins Center for Mendelian Genomics, Boerwinkle E, Eissa NT, Gibbs RA, Lupski JR, Orange JS, Shum AK PMID: 25894502

Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic. (25886082)

Sorenson E, Koo J PMID: 25886082

Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction. (25857745)

Rouhani SJ, Eccles JD, Riccardi P, Peske JD, Tewalt EF, Cohen JN, Liblau R, Mäkinen T, Engelhard VH PMID: 25857745

Sebaceous induction in dermatofibroma: a common feature of dermatofibromas on the shoulder. (25727075)

Zeidi M, North JP PMID: 25727075

Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. (25643237)

Yue L, Huang ZM, Fong S, Leong S, Jakowatz JG, Charruyer-Reinwald A, Wei M, Ghadially R PMID: 25643237

Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. (25643237)

Yue L, Huang ZM, Fong S, Leong S, Jakowatz JG, Charruyer-Reinwald A, Wei M, Ghadially R PMID: 25643237

The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes. (25517516)

Sanlorenzo M, Vujic I, Posch C, Cleaver JE, Quaglino P, Ortiz-Urda S PMID: 25517516

What dermatology still needs to create meaningful patient outcome measurements. (25549325)

Resneck JS, VanBeek M PMID: 25549325

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. (25867272)

Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI PMID: 25867272

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. (25867272)

Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI PMID: 25867272